Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018094 | 1.00 | KDM4E (0.50) | KDM4EKEAP1GLAIDO1KMT2A | |
| Hydrochloric Acid SCHEMBL21494383 | 0.98 | KDM4E (0.48) | KDM4EKEAP1GLAIDO1KMT2A | |
| SCHEMBL2726898 | 0.92 | KDM4E (0.50) | KDM4EKEAP1GLAIDO1KMT2A | |
| Hydrochloric Acid SCHEMBL18954184 | 0.90 | KDM4E (0.48) | KDM4EKEAP1GLAIDO1KMT2A | |
| SCHEMBL20327005 | 0.84 | DGAT1 (0.48) | KDM4EKEAP1GLAALDH1A1CA1 | |
| SCHEMBL17049160 | 0.84 | KDM4E (0.46) | KDM4EKEAP1GLAIDO1KMT2A | |
| SCHEMBL24697741 | 0.83 | KEAP1 (0.45) | KDM4EKEAP1GLAKMT2AMEN1 | |
| SCHEMBL1047232 | 0.83 | KDM4E (0.57) | KDM4EKEAP1GLAIDO1KMT2A | |
| SCHEMBL222733 | 0.83 | KEAP1 (0.57) | KDM4EKEAP1GLAIDO1KMT2A | |
| SCHEMBL21513677 | 0.82 | DGAT1 (0.35) | KDM4EKEAP1GLADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| CN-120058795-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058797-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120058796-A | Phosphorus-containing SOS1 inhibitors | 正大天晴药业集团股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-1687305-B1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| CN-1902200-A | 1h-imidazoquinoline derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| CN-1882586-A | 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | KDM4E 1054/4885KEAP1 616/4885GLA 4428/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | KDM4E 3399/4885KEAP1 1521/4885GLA 1079/4885 |
| US-12291529-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, IAPP | KDM4E 3866/4885KEAP1 2892/4885GLA 1044/4885 |
| US-20250368634-A1 | PHENYL AMIDE COMPOUNDS AND METHODS OF USE | AADAC, DBI, ASNS | KDM4E 1995/4885KEAP1 3214/4885GLA 2518/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 2782/4885KEAP1 298/4885GLA 3535/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | KDM4E 3237/4885KEAP1 249/4885GLA 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.